TrialNeurology2025
Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
Scott D Newsome et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
TrialNeurology2025
Scott D Newsome et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.